Ropinirole, a Non-ergoline Dopamine Agonist

Overview

Journal CNS Drug Rev

Specialties Neurology
Pharmacology

Date 2006 Jan 4

PMID 16389293

Citations 7

Authors

Wolfgang H Jost

Dieter Angersbach

Affiliations

Soon will be listed here.

Abstract

Dopamine agonists have become indispensable in the treatment of Parkinson's disease. In every-day practice, however, the decision to select the best compound for an individual patient is rendered difficult because of the large number of substances available on the market. This review article provides a closer look at the experimental and clinical studies with ropinirole published so far. Ropinirole is a non-ergoline dopamine agonist which has been proven to be effective in both, monotherapy and combination therapy of idiopathic Parkinson's disease. In addition to ameliorating bradykinesia, rigor, and tremor, ropinirole facilitates the daily life and improves depressive moods of patients with Parkinson's disease. The long-term complications of levodopa are avoided, and problems commonly associated with levodopa treatment are reduced. Ropinirole appears to have a neuroprotective effect. In addition to Parkinson's disease, ropinirole has also been used successfully in the treatment of restless legs syndrome.

Citing Articles

Neurotransmitters crosstalk and regulation in the reward circuit of subjects with behavioral addiction.

Peng Z, Jia Q, Mao J, Luo X, Huang A, Zheng H Front Psychiatry. 2025; 15:1439727.

PMID: 39876994 PMC: 11773674. DOI: 10.3389/fpsyt.2024.1439727.

Nanoparticle-Guided Brain Drug Delivery: Expanding the Therapeutic Approach to Neurodegenerative Diseases.

Riccardi C, Napolitano F, Montesarchio D, Sampaolo S, Melone M Pharmaceutics. 2021; 13(11).

PMID: 34834311 PMC: 8623286. DOI: 10.3390/pharmaceutics13111897.

Ropinirole-Associated Orthostatic Hypotension as Cause of a Prescribing Cascade in an Elderly Man.

Becerra A, Boch M, Al-Mezrakchi Y Cureus. 2021; 13(6):e15506.

PMID: 34268037 PMC: 8261795. DOI: 10.7759/cureus.15506.

Increased risk for developing gambling disorder under the treatment with pramipexole, ropinirole, and aripiprazole: A nationwide register study in Sweden.

Wolfschlag M, Hakansson A PLoS One. 2021; 16(6):e0252516.

PMID: 34061895 PMC: 8168838. DOI: 10.1371/journal.pone.0252516.

Overcoming the Blood-Brain Barrier: Functionalised Chitosan Nanocarriers.

Caprifico A, Foot P, Polycarpou E, Calabrese G Pharmaceutics. 2020; 12(11).

PMID: 33114020 PMC: 7690755. DOI: 10.3390/pharmaceutics12111013.

References

Taylor A, Beerahee A, Citerone D, Davy M, Fitzpatrick K, Lopez-Gil A . The effect of steady-state ropinirole on plasma concentrations of digoxin in patients with Parkinson's disease. Br J Clin Pharmacol. 1999; 47(2):219-22. PMC: 2014176. DOI: 10.1046/j.1365-2125.1999.00867.x. View

Goetz C, Blasucci L, Stebbins G . Switching dopamine agonists in advanced Parkinson's disease: is rapid titration preferable to slow?. Neurology. 1999; 52(6):1227-9. DOI: 10.1212/wnl.52.6.1227. View

Frucht S, Rogers J, Greene P, Gordon M, Fahn S . Falling asleep at the wheel: motor vehicle mishaps in persons taking pramipexole and ropinirole. Neurology. 1999; 52(9):1908-10. DOI: 10.1212/wnl.52.9.1908. View

Thalamas C, Taylor A, Brefel-Courbon C, Eagle S, Fitzpatrick K, Rascol O . Lack of pharmacokinetic interaction between ropinirole and theophylline in patients with Parkinson's disease. Eur J Clin Pharmacol. 1999; 55(4):299-303. DOI: 10.1007/s002280050632. View

Korczyn A, Brunt E, Larsen J, Nagy Z, Poewe W, Ruggieri S . A 3-year randomized trial of ropinirole and bromocriptine in early Parkinson's disease. The 053 Study Group. Neurology. 1999; 53(2):364-70. DOI: 10.1212/wnl.53.2.364. View

Canesi M, Antonini A, Mariani C, Tesei S, Zecchinelli A, Barichella M . An overnight switch to ropinirole therapy in patients with Parkinson's disease. Short communication. J Neural Transm (Vienna). 1999; 106(9-10):925-9. DOI: 10.1007/s007020050212. View

Lund B, Neiman R, Perry P . Treatment of Parkinson's disease with ropinirole after pergolide-induced retroperitoneal fibrosis. Pharmacotherapy. 1999; 19(12):1437-8. DOI: 10.1592/phco.19.18.1437.30888. View

Rascol O, Brooks D, Korczyn A, De Deyn P, Clarke C, Lang A . A five-year study of the incidence of dyskinesia in patients with early Parkinson's disease who were treated with ropinirole or levodopa. N Engl J Med. 2000; 342(20):1484-91. DOI: 10.1056/NEJM200005183422004. View

Saletu B, Gruber G, Saletu M, Brandstatter N, Hauer C, Prause W . Sleep laboratory studies in restless legs syndrome patients as compared with normals and acute effects of ropinirole. 1. Findings on objective and subjective sleep and awakening quality. Neuropsychobiology. 2000; 41(4):181-9. DOI: 10.1159/000026658. View

10.

Jost W . Equivalent doses of ropinirole and bromocriptine. Eur J Neurol. 2000; 6(5):618. DOI: 10.1046/j.1468-1331.1999.650618.x. View

11.

Hubble J, Koller W, Atchison P, Taylor A, Citerone D, Zussman B . Linear pharmacokinetic behavior of ropinirole during multiple dosing in patients with Parkinson's disease. J Clin Pharmacol. 2000; 40(6):641-6. View

12.

MATHESON A, Spencer C . Ropinirole: a review of its use in the management of Parkinson's disease. Drugs. 2000; 60(1):115-37. DOI: 10.2165/00003495-200060010-00007. View

13.

Rogers D, Costall B, Domeney A, Gerrard P, Greener M, Kelly M . Anxiolytic profile of ropinirole in the rat, mouse and common marmoset. Psychopharmacology (Berl). 2000; 151(1):91-7. DOI: 10.1007/s002130000485. View

14.

Kaye C, Nicholls B . Clinical pharmacokinetics of ropinirole. Clin Pharmacokinet. 2000; 39(4):243-54. DOI: 10.2165/00003088-200039040-00001. View

15.

Clarke C, Deane K . Ropinirole versus bromocriptine for levodopa-induced complications in Parkinson's disease. Cochrane Database Syst Rev. 2001; (1):CD001517. DOI: 10.1002/14651858.CD001517. View

16.

Perugi G, Toni C, Ruffolo G, Frare F, Akiskal H . Adjunctive dopamine agonists in treatment-resistant bipolar II depression: an open case series. Pharmacopsychiatry. 2001; 34(4):137-41. DOI: 10.1055/s-2001-15872. View

17.

Mungersdorf M, Sommer U, Sommer M, Reichmann H . High-dose therapy with ropinirole in patients with Parkinson's disease. J Neural Transm (Vienna). 2002; 108(11):1309-17. DOI: 10.1007/s007020100007. View

18.

Gimenez-Roldan S, Esteban E, Mateo D . Switching from bromocriptine to ropinirole in patients with advanced Parkinson's disease: open label pilot responses to three different dose-ratios. Clin Neuropharmacol. 2002; 24(6):346-51. DOI: 10.1097/00002826-200111000-00006. View

19.

Schapira A . Neuroprotection and dopamine agonists. Neurology. 2002; 58(4 Suppl 1):S9-18. DOI: 10.1212/wnl.58.suppl_1.s9. View

20.

Elble R . Tremor and dopamine agonists. Neurology. 2002; 58(4 Suppl 1):S57-62. DOI: 10.1212/wnl.58.suppl_1.s57. View